Obesity is increasingly being treated with pills rather than injections, according to a new review published in Cardiovascular Diabetology. The article, authored by Shivangi Pande, Malik Hyman and colleagues under the senior guidance of Gaetano Santulli, argues that recent advances in oral pharmacotherapy have significantly changed the therapeutic approach to obesity, with GLP-1 receptor agonists emerging as highly effective agents capable of achieving clinically meaningful and durable weight loss.
The review highlights a pivotal regulatory milestone: the recent FDA approvals of oral GLP-1 receptor agonists, including semaglutide and orforglipron. According to the authors, these approvals represent an important step forward by providing effective oral alternatives to injectable therapies and further broadening the range of treatment options available to clinicians and patients.
The authors frame obesity as a complex, chronic and progressive disease characterized by persistent disturbances in energy regulation and metabolism. They note that these disturbances contribute substantially to the development of cardiovascular, metabolic and other complications, which is why the disease requires long-term management rather than short-term intervention.
A central theme of the review is why lifestyle modification alone often falls short. The authors state that sustained weight reduction remains challenging for many individuals, largely due to biological adaptations that counteract weight loss and favor weight regain over time. This biological resistance, they argue, is precisely why pharmacotherapy has become an essential component of modern obesity care.
Among the key points emphasized in the paper is that obesity requires long-term, multifaceted treatment strategies because lifestyle interventions alone are often insufficient to achieve and maintain meaningful weight loss. The review positions this as the foundation upon which newer drug therapies are being layered.
The review also stresses accessibility. Advances in oral anti-obesity medications, particularly GLP-1-based therapies, are described as transforming obesity care by providing effective and more accessible treatment options. Oral dosing removes the need for injections, which the authors suggest may broaden the reach of effective therapy to more patients.
Beyond currently approved agents, the authors survey novel oral therapies in late-stage clinical development. They caution that these emerging treatments are still in development, but they argue that such therapies may further expand treatment choices and enable more personalized approaches to obesity management in the future.
Methodologically, the paper is a comprehensive review rather than a clinical trial. It provides a systematic overview of currently available oral anti-obesity medications and novel oral agents in late-stage development, discussing their mechanisms of action, efficacy, safety considerations and potential role in contemporary obesity management. As a review, it synthesizes existing evidence rather than presenting new trial data of its own.
The article was published on 21 October 2026 as an open-access review in Cardiovascular Diabetology, and the publisher notes that this early version is subject to further edits before the final Version of Record. For clinicians and researchers tracking the field, the review’s central message is that the era of effective oral obesity pharmacotherapy has arrived, anchored by approved oral GLP-1 receptor agonists and reinforced by a pipeline of agents still moving through late-stage clinical testing.
Subject of Research: Oral pharmacotherapy, including GLP-1 receptor agonists, for the treatment of obesity
Article Title: Beyond injectable therapies: the emerging role of oral pharmacotherapy in the modern treatment of obesity
Article References: Pande, S., Hyman, M., Danza, M. L., Jankauskas, S. S., Dragonetti, L., Mone, P., Kansakar, U., Volpe, E., & Santulli, G. (2026). Beyond injectable therapies: the emerging role of oral pharmacotherapy in the modern treatment of obesity. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-026-03410-x
Image Credits: AI Generated
DOI: 10.1186/s12933-026-03410-x
Keywords: obesity, oral pharmacotherapy, GLP-1 receptor agonists, semaglutide, orforglipron, FDA approval, weight loss, cardiovascular risk, drug development, review, Beyond, injectable
News Source: Daisy Hatcher. (October 29, 2026). Oral GLP-1 therapies reshape obesity treatment, review finds. Scienmag.
